新诊断类风湿性关节炎患者单核细胞中TNFSF12/TWEAK、CD163的表达及意义

IF 2.1 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-09-01 Epub Date: 2025-09-18 DOI:10.1080/17520363.2025.2562556

Tingting Zeng, Lulu Zeng, Qianbin Dai, Yao Zhou, Qing Luo, Lu Zhang

{"title":"新诊断类风湿性关节炎患者单核细胞中TNFSF12/TWEAK、CD163的表达及意义","authors":"Tingting Zeng, Lulu Zeng, Qianbin Dai, Yao Zhou, Qing Luo, Lu Zhang","doi":"10.1080/17520363.2025.2562556","DOIUrl":null,"url":null,"abstract":"Aim: A retrospective study was designed to compare the expression levels of TNF superfamily member 12 (TNFSF12), which encodes the protein TNF-like weak inducer of apoptosis (TWEAK), and CD163 in peripheral blood monocytes between rheumatoid arthritis (RA) patients and controls, and to correlate their expression with clinical parameters to investigate their potential association with RA.Materials & methods: RT-qPCR method was used to determine gene expression of TNFSF12 and CD163 in patients with RA, ankylosing spondylitis (AS) and healthy controls (HC). ROC curve, Pearson correlation analysis, and western blot were used to access the diagnostic performance of TNFSF12/TWEAK and CD163, analyze their correlation with other clinical parameters in RA, and evaluate the protein expression of TWEAK and CD163 in RA.Results: TNFSF12 and CD163 in RA patients were higher expressed compared with AS and HC; they were helpful to identify RA patients from controls, with area under ROC curve (AUC) being 0.813 and 0.826, respectively, and correlated with ESR and CRP. TWEAK and CD163 in monocytes from RA were significantly upregulated compared with controls.Conclusion: TNFSF12 and CD163 gene higher expressed in RA patients and related with therapeutic response and inflammation status, can be used as reference index for RA diagnosis and disease monitoring.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"857-865"},"PeriodicalIF":2.1000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477863/pdf/","citationCount":"0","resultStr":"{\"title\":\"Expression and significance of TNFSF12/TWEAK, CD163 in monocytes of patients with newly diagnosed rheumatoid arthritis.\",\"authors\":\"Tingting Zeng, Lulu Zeng, Qianbin Dai, Yao Zhou, Qing Luo, Lu Zhang\",\"doi\":\"10.1080/17520363.2025.2562556\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: A retrospective study was designed to compare the expression levels of TNF superfamily member 12 (TNFSF12), which encodes the protein TNF-like weak inducer of apoptosis (TWEAK), and CD163 in peripheral blood monocytes between rheumatoid arthritis (RA) patients and controls, and to correlate their expression with clinical parameters to investigate their potential association with RA.Materials & methods: RT-qPCR method was used to determine gene expression of TNFSF12 and CD163 in patients with RA, ankylosing spondylitis (AS) and healthy controls (HC). ROC curve, Pearson correlation analysis, and western blot were used to access the diagnostic performance of TNFSF12/TWEAK and CD163, analyze their correlation with other clinical parameters in RA, and evaluate the protein expression of TWEAK and CD163 in RA.Results: TNFSF12 and CD163 in RA patients were higher expressed compared with AS and HC; they were helpful to identify RA patients from controls, with area under ROC curve (AUC) being 0.813 and 0.826, respectively, and correlated with ESR and CRP. TWEAK and CD163 in monocytes from RA were significantly upregulated compared with controls.Conclusion: TNFSF12 and CD163 gene higher expressed in RA patients and related with therapeutic response and inflammation status, can be used as reference index for RA diagnosis and disease monitoring.\",\"PeriodicalId\":9182,\"journal\":{\"name\":\"Biomarkers in medicine\",\"volume\":\" \",\"pages\":\"857-865\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477863/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biomarkers in medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/17520363.2025.2562556\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2562556","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：通过一项回顾性研究，比较类风湿关节炎（RA）患者和对照组外周血单核细胞中TNF超家族成员12 （TNFSF12）和CD163的表达水平，并将其表达与临床参数相关联，探讨其与RA的潜在关联。TNFSF12编码TNF样细胞凋亡弱诱导剂蛋白（TWEAK）。材料与方法：采用RT-qPCR法检测RA、强直性脊柱炎（AS）和健康对照（HC）患者中TNFSF12和CD163的基因表达。采用ROC曲线、Pearson相关分析、western blot分析TNFSF12/TWEAK和CD163的诊断效能，分析其与RA其他临床参数的相关性，评估TWEAK和CD163在RA中的蛋白表达。结果：RA患者中TNFSF12和CD163的表达高于AS和HC；其ROC曲线下面积（area under ROC curve， AUC）分别为0.813和0.826，与ESR和CRP相关。与对照组相比，RA单核细胞中的TWEAK和CD163显著上调。结论：TNFSF12和CD163基因在RA患者中表达较高，且与治疗反应和炎症状态相关，可作为RA诊断和疾病监测的参考指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expression and significance of TNFSF12/TWEAK, CD163 in monocytes of patients with newly diagnosed rheumatoid arthritis.

Aim: A retrospective study was designed to compare the expression levels of TNF superfamily member 12 (TNFSF12), which encodes the protein TNF-like weak inducer of apoptosis (TWEAK), and CD163 in peripheral blood monocytes between rheumatoid arthritis (RA) patients and controls, and to correlate their expression with clinical parameters to investigate their potential association with RA.

Materials & methods: RT-qPCR method was used to determine gene expression of TNFSF12 and CD163 in patients with RA, ankylosing spondylitis (AS) and healthy controls (HC). ROC curve, Pearson correlation analysis, and western blot were used to access the diagnostic performance of TNFSF12/TWEAK and CD163, analyze their correlation with other clinical parameters in RA, and evaluate the protein expression of TWEAK and CD163 in RA.

Results: TNFSF12 and CD163 in RA patients were higher expressed compared with AS and HC; they were helpful to identify RA patients from controls, with area under ROC curve (AUC) being 0.813 and 0.826, respectively, and correlated with ESR and CRP. TWEAK and CD163 in monocytes from RA were significantly upregulated compared with controls.

Conclusion: TNFSF12 and CD163 gene higher expressed in RA patients and related with therapeutic response and inflammation status, can be used as reference index for RA diagnosis and disease monitoring.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.